CYPEX Limited

F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the Company’s goal is to offer patients with cancer greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating best-in-class drug candidates with broad therapeutic index and monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for patients with cancer.

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

Abliance masters essential technologies to develop new generation antibodies. Our team of experts closely works with research laboratories, diagnostic industry, actors of clinical research and biopharmaceutical industry to understand the needs associated with each application, its regulatory environment and economic constraints. Abliance provides antibodies that perform in their application by designing unique solutions.

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology.

The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.

Founded in 2006, Abyntek Biopharma S.L. is a private Spanish company aimed at providing an integral and personalized service in the supply of antibodies.
Our company has two main business lines. On one hand, we are distributors of over twenty companies offering a comprehensive catalogue of more than 2 million antibodies, ELISA kits and proteins in general. On the other hand, we are the Spanish leading provider of custom monoclonal and polyclonal antibodies for R&D use. To this end, Abyntek can synthesize the necessary antigens (proteins and peptides) or make use of the client´s. We also offer antibody modifications such as biotinylation or conjugation to fluorophores and enzymes.
Come to visit our webpage (www.abyntek.com) and learn more about us. If you have any antibodies need, our international scientific team will be glad to help you!
Contact us and enjoy the experience of a special treat.

Abyntek on Twitter: bit.ly/1rummfr